Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Immunomedics, Inc.
EMA Backs Approval For Eight New Drugs But Rejects Lagevrio For COVID-19
Janssen’s Akeega is among the latest drugs that the European Medicines Agency says should be approved for use in the EU. Meanwhile, MSD/Ridgeback Biotherapeutics plan to appeal the agency’s rejection of their COVID-19 treatment.
Deal Watch: Moderna, ElevateBio Subsidiary To Combine mRNA With Gene Editing
Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.
Biogen's Return Of Rights To InnoCare Deals Blow To Made In China Innovation
Biogen’s return of rights to the BTK inhibitor orelabrutinib to originator InnoCare signals an ongoing tough reality for Chinese biotechs with go-global ambitions.
Gilead’s Trodelvy Strategy Helped By Phase II Bladder Cancer Data
Two weeks after obtaining its third cancer indication and the same day Kite CEO Christi Shaw’s departure was announced, Gilead’s antibody-drug conjugate yielded Phase II data it says will help toward full approval in urothelial cancer.
- Radiopharmaceuticals, Contrast Agents
- Large Molecule
- Other Names / Subsidiaries
- IBC Pharmaceuticals, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.